Sunday, August 28, 2016

Roth starts Actinium Pharma at buy

Roth starts Actinium Pharma at buy

August 25, 2016 by · Leave a Comment 

Tweet Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday. “We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data […]

Analysts start Tactile Systems at buy, outperform

Analysts start Tactile Systems at buy, outperform

August 22, 2016 by · Leave a Comment 

Tweet Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively. Tactile makes pneumatic compression devices (PCD) to treat lymphedema, along with a chronic venous leg ulcer product. Tactile closed an IPO of 4,120,000 shares at $10 apiece earlier this month. The […]

IntelGenx has positive pilot study with montelukast film

IntelGenx has positive pilot study with montelukast film

August 22, 2016 by · Leave a Comment 

Tweet IntelGenx (OTCQX:IGXT; TSX-V:IGX) has completed a pilot clinical study for montelukast VersaFilm that demonstrated a significantly improved pharmacokinetic profile against the reference product. Montelukast is a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer’s disease. The study data confirmed that buccal absorption […]

Leerink upgrades Cardiovascular Systems to outperform

Leerink upgrades Cardiovascular Systems to outperform

August 22, 2016 by · Leave a Comment 

Tweet Leerink Partners upgraded Cardiovascular Systems (NASDAQ:CSII) to “outperform” and raised its price target to $30 from $23. The stock closed at $22.60 on Friday. “Now with two solid quarters in a row of stable-to-improving growth and a new CEO in place, we believe the company has reached a fundamental inflection point after several quarters […]

WB starts 4 chronic Hep B biotechs at outperform

WB starts 4 chronic Hep B biotechs at outperform

August 19, 2016 by · Leave a Comment 

Tweet William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier. “Curing chronic hepatitis B infections is the next frontier after solving the hepatitis C problem, and the markets for both disease cures could be similar in size, reaching $200-billion each in cumulative […]

Leerink downgrades Mirna to market perform

Leerink downgrades Mirna to market perform

August 17, 2016 by · Leave a Comment 

Tweet Leerink Partners downgraded Mirna Therapeutics (NASDAQ:MIRN) to “market perform” from “outperform” and lowered its price target to $4 from $10, citing added uncertainties around the development path and safety profile of lead product candidate, MRX34. The stock closed at $3.95 on Tuesday. “While microRNAs represent an intriguing emerging new class of therapeutic targets, recent […]

StemCells and Microbot Medical to merge

StemCells and Microbot Medical to merge

August 16, 2016 by · Leave a Comment 

Tweet StemCells (NASDAQ:STEM) and closely-held Microbot Medical of Israel have entered into a definitive merger agreement, with plans to pursue the development of robotics-based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, as well as other conditions. “This transaction concludes an extensive search for strategic alternatives conducted by StemCells since we failed […]

WB drops coverage of OncoGenex

WB drops coverage of OncoGenex

August 16, 2016 by · Leave a Comment 

Tweet William Blair dropped coverage of OncoGenex (NASDAQ:OGXI) after the company announced that the AFFINITY study did not meet the primary endpoint. The stock closed at 90 cents on Monday. “We note that AFFINITY is the key study of the lead asset, custirsen, as a chemotherapy companion in the second-line chemo setting in metastatic castration […]

Profound Medical names Arun Menawat as CEO

Profound Medical names Arun Menawat as CEO

August 15, 2016 by · Leave a Comment 

Tweet Profound Medical (TSX-V:PRN) appointed Arun Menawat as its new CEO.  Steven Plymale, the company’s current CEO, will transition to President and COO. Dr. Menawat has been a member of Profound’s board since October 2014. Most recently, he was president and CEO of Novadaq Technologies, which pioneered the field of fluorescence imaging in the operating […]

Leerink reiterates rating on Aurinia following trial results

Leerink reiterates rating on Aurinia following trial results

August 15, 2016 by · Leave a Comment 

Tweet Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the reported top-line results with voclosporin in a Phase 2b clinical study in patients with active lupus nephritis. Analyst Joseph Schwartz writes that the study met its primary endpoint of complete remission and improvements in partial remission versus placebo. While efficacy was higher […]

Next Page »

Email Newsletters with Constant Contact
Google+